Adagio Therapeutics Stock News

Adagio Therapeutics Inc. (NASDAQ:ADGI)’s traded shares stood at 11.92 million during the last session. At the close of trading, the stock’s price was $7.34, to imply a decrease of -31.85% or -$3.43 in intraday trading. The ADGI share’s 52-week high remains $78.82, putting it -973.84% down since that peak but still an impressive 32.97% since … Adagio Therapeutics Inc. (NASDAQ: ADGI) Drops -973.84% From Highs, What Happens Next? Read More »

Volatility in trading of Adagio Therapeutics is continuing today as shares have dropped significantly in early afternoon trading.

Gainers US Ecology, Inc. (NASDAQ: ECOL ) shares jumped 68.1% to $47.34 after Republic Services reported it will buy the company at $48 per share in cash. Tritium DCFC Limited (NASDAQ: DCFC ) gained 65.4% to $15.78. Tritium DCFC shares surged nearly 40% Tuesday after the Australian EV charging company announced its new manufacturing facility will be located in the United States. Tritium CEO Jane Hunter appeared at the White House to make the announcement yesterday. Infobird Co., Ltd (NASDAQ: IFBD ) gained 32.6% to $1.2393. Infobird recently signed a contract with subsidiary of Nippi Japan for digital marketing solutions. Doximity, Inc. (NYSE: DOCS ) shares gained 25.1% to $62.30 after the company reported better-than-expected Q3 results and issued FY22 sales guidance above estimates. Aptevo Therapeutics Inc. (NASDAQ: APVO ) jumped 20.5% to $7.29 after the company announced it has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE. Absolute Software Corporation (NASDAQ: ABST ) gained 17.9% to $9.47 after the company reported better-than-expected Q2 sales results and issued FY22 sales guidance.

Adagio Therapeutics so far in 2022 is managing to do something most of its peers havent been able to -- increase in value.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

Digital World Acquisition, ZIM Integrated Shipping Services, Adagio Therapeutics, Roblox, and Doximity saw the largest percentage increase in stock price since initial listing.

The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19.

Trading in Adagio Therapeutics has been on a roller coaster ride over the last week, though today, the bulls are ahead.

The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19.

Could these biotech stocks be poised for gains in 2022?

Adagio Therapeutics Inc (NASDAQ: ADGI ) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron variant. Adagio shares lost almost 80% after it announced a greater than 300-fold reduction in neutralizing activity of ADG20 against omicron. Recently published in vitro studies examined the neutralization potencies of large panels of mAbs against the omicron variant. Findings across all three studies show that among mAbs in late-stage development or Emergency Use Full story available on Benzinga.com

The stock price of Adagio Therapeutics Inc (NASDAQ: ADGI) increased by over 16% during intraday trading today. This is why it happened.

Adagio Therapeutics (ADGI) said three separate publications that show that its lead monoclonal antibody (mAb) ADG20 has neutralization activity against the Omicron (B.1.1.529) variant…

Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron Multiple Efforts Underway to Address Omicron and Potential Future SARS-CoV-2 Variants WALTHAM, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ: ADGI ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today summarized recent findings reported in three separate publications that show ADG20, its lead monoclonal antibody (mAb), has neutralization activity against the Omicron (B.1.1.529) variant of SARS-CoV-2, and outlined initiatives to address current and future SARS-CoV-2 variants of concern. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Adagio is engaging with the U.S. Food and Drug Administration (FDA) regarding potential protocol updates to its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 resulting from the Omicron variant.

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ: ADGI ) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., chief executive officer of Adagio, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 a.m. ET. A live webcast will be available in the investor section Full story available on Benzinga.com